FOREIGN PRODUCERS'/EXPORTERS' QUESTIONNAIRE

SILICOMANGANESE FROM CHINA AND UKRAINE

This questionnaire must be received by the Commission by <u>July 12, 2024</u>
See last page for instructions regarding how to file this questionnaire.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its reviews of the antidumping duty orders concerning silicomanganese from China and Ukraine (Inv. Nos. 731-TA-672-673 (Fifth Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII.

Address		
Website		
Has your firm time since Jan	produced or exported silicomanganese (as defined cuary 1, 2018?	on next page) from China or Ukraine at any
■ NO	(Sign the certification below and promptly return only th	nis page of the questionnaire to the Commission)
YES	(Complete all parts of the questionnaire, and return the	entire questionnaire to the Commission)
Data reporte	d in this questionnaire relate to (Check one):	
	☐ China	Ukraine
	CERTIFICATION	
lge and belief an of this certificati tion provided in	nation herein supplied in response to this quest d understand that the information submitted is su on I also grant consent for the Commission, an	ionnaire is complete and correct to the best of my object to audit and verification by the Commission. By d its employees and contract personnel, to use the ng in any other import-injury proceedings or reviews
lge and belief and of this certification provided in ed by the Commistration or other proceed (a) for develop and evaluation ix 3; or (ii) by U.S.	nation herein supplied in response to this quest d understand that the information submitted is su fon I also grant consent for the Commission, and this questionnaire and throughout this proceedings ion on the same or similar merchandise. Towledge that information submitted in response seeding may be disclosed to and used: (i) by the poing or maintaining the records of this or a relater is relating to the programs, personnel, and ope	abject to audit and verification by the Commission. By d its employees and contract personnel, to use the
lge and belief and of this certification provided in ed by the Commistration or other proceed (a) for develop and evaluation ix 3; or (ii) by U.S.	nation herein supplied in response to this quest d understand that the information submitted is sufficient I also grant consent for the Commission, and this questionnaire and throughout this proceedingsion on the same or similar merchandise. owledge that information submitted in response ceeding may be disclosed to and used: (i) by the bing or maintaining the records of this or a relate is relating to the programs, personnel, and ope is government employees and contract personnel, and appropriate nondisclosure agreements.	to this request for information and throughout this commission. By the commission. By the this request for information and throughout this Commission, its employees and Offices, and contract d proceeding, or (b) in internal investigations, audits, rations of the Commission including under 5 U.S.C.
lge and belief and of this certification provided in ed by the Commismed, acknown ing or other proceed (a) for developing and evaluation ix 3; or (ii) by U.S. personnel will signal.	nation herein supplied in response to this quest d understand that the information submitted is sure on I also grant consent for the Commission, and this questionnaire and throughout this proceedingsion on the same or similar merchandise. Towledge that information submitted in response ceeding may be disclosed to and used: (i) by the pring or maintaining the records of this or a relate is relating to the programs, personnel, and ope is government employees and contract personnel, and appropriate nondisclosure agreements.	abject to audit and verification by the Commission. By d its employees and contract personnel, to use the ag in any other import-injury proceedings or reviews to this request for information and throughout this Commission, its employees and Offices, and contract d proceeding, or (b) in internal investigations, audits, rations of the Commission including under 5 U.S.C. solely for cybersecurity purposes. I understand that all

PART I.—GENERAL INFORMATION

Background. —On December 22, 1994, the Department of Commerce ("Commerce") issued an antidumping duty order on imports of silicomanganese from China, and on September 17, 2001, Commerce issued an antidumping duty order on imports of silicomanganese from Ukraine. On November 1, 2023, the Commission instituted reviews pursuant to section 751(c) of the Tariff Act of 1930 (19 U.S.C. § 1675(c)) to determine whether revocation of the orders would be likely to lead to continuation or recurrence of material injury to the domestic industry within a reasonably foreseeable time. If both the Commission and Commerce make an affirmative determination, the orders will remain in place. If either the Commission or Commerce makes a negative determination, Commerce will revoke the orders. Pertinent information to this proceeding is available at:

Questionnaires: https://usitc.gov/reports/active import injury questionnaires. Other case information: https://ids.usitc.gov/case/367/investigation/8476

<u>Silicomanganese</u> covered by this proceeding is silicomanganese, which is sometimes called ferrosilicon manganese, a ferroalloy composed principally of manganese, silicon, and iron, and normally contains much smaller proportions of minor elements, such as carbon, phosphorus and sulfur. Silicomanganese generally contains by weight not less than 4 percent iron, more than 30 percent manganese, more than 8 percent silicon and not more than 3 percent phosphorus. All compositions, forms and sizes of silicomanganese are included within the scope of these orders, including silicomanganese slag, fines, and briquettes. Silicomanganese is used primarily in steel production as a source of both silicon and manganese.

Silicomanganese is currently imported under subheading 7202.30.0000 of the Harmonized Tariff Schedule of the United States (HTSUS). Some silicomanganese may also be imported under HTSUS subheading 7202.99.8040. The orders cover all silicomanganese, regardless of its tariff classification. Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the orders remains dispositive.

Reporting of information. —If information is not readily available from your records, provide carefully prepared estimates. If your firm is completing more than one questionnaire (i.e., a producer, importer, purchaser and/or foreign producer questionnaire), you need not respond to duplicated questions.

Confidentiality. —The commercial and financial data furnished in response to this questionnaire that reveal the individual operations of your firm will be treated as confidential by the Commission to the extent that such data are not otherwise available to the public and will not be disclosed except as may be required by law (see 19 U.S.C. § 1677f). Such confidential information will not be published in a manner that will reveal the individual operations of your firm; however, general characterizations of numerical business proprietary information (such as discussion of trends) will be treated as confidential business information only at the request of the submitter for good cause shown.

<u>Verification</u>. —The information submitted in this questionnaire is subject to audit and verification by the Commission. To facilitate possible verification of data, please keep all files, worksheets, and supporting documents used in the preparation of the questionnaire response. Please also retain a copy of the final document that you submit.

Release of information.—The information provided by your firm in response to this questionnaire, as well as any other business proprietary information submitted by your firm to the Commission in connection with this proceeding, may become subject to, and released under, the administrative protective order provisions of the Tariff Act of 1930 (19 U.S.C. § 1677f) and section 207.7 of the Commission's Rules of Practice and Procedure (19 CFR § 207.7). This means that certain lawyers and other authorized individuals may temporarily be given access to the information for use in connection with this proceeding or other import-injury proceedings conducted by the Commission on the same or similar merchandise; those individuals would be subject to severe penalties if the information were divulged to unauthorized individuals.

I-1. Reporting requirements. —Please report below the actual number of hours required and the cost to your firm of completing this questionnaire for use by the Office of Management and Budget.

Hours	Dollars	

Public reporting burden for this questionnaire is estimated to average 30 hours per response, including the time for reviewing instructions, gathering data, and completing and reviewing the questionnaire.

We welcome comments regarding the accuracy of this burden estimate, suggestions for reducing the burden, and any suggestions for improving this questionnaire. Please provide such comments to the Office of Investigations, import injury@usitc.gov.

I-2. <u>Establishments covered</u>. —Provide the name and address of establishment(s) covered by this questionnaire.

" <u>Establishment</u> " — Each facility of a firm in China or Ukraine involved in the production or
export of silicomanganese, including auxiliary facilities operated in conjunction with (whether or
not physically separate from) such facilities. Firms operating more than one establishment in
China or Ukraine should combine the data for all establishments into a single report.

I-3.	Stock symbol information. — If your firm or any of the entities reported in question I-2 are
	publicly traded in the United States, please specify the stock exchange and trading symbol
	(including American Depository Receipts, if applicable):

I-4.	External counsel. — If your firm or parent firm is represented by external counsel in relation to
	this proceeding, please specify the name of the law firm and the lead attorney(s).

Law firm:	
Lead attorney(s):	

I-5. <u>U.S. importers.</u> —Please provide the names, contacts, email addresses, and telephone numbers of the <u>TEN</u> largest U.S. importers of your firm's silicomanganese since January 1, 2018.

No.	Importer's name	Contact person	Email address	Area code and telephone number	Share of your firm's 2023 U.S. exports (%)
1					
2					
3					
4					
5					
6					
7					
8					
9					
10					

"Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.

I-6. Related producers. —Does your firm or any related firm produce, have the capability to produce, or have any plans to produce silicomanganese in the United States or other countries?

No	Yes	If yes—Please name the firm(s) and country(ies) below and, if U.S. producer(s), ensure that they complete the Commission's U.S. producer questionnaire.

I-7. Related U.S. importers. —Does your firm or any related firm import or have any plans to import silicomanganese into the United States?

No	If yes—Please name the firm(s) below and ensure that they complete the Commission's importer questionnaire.

PART II. —TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from Tyler Berard (202-205-3354), Tyler.Berard@usitc.gov). Supply all data requested on a calendar-year basis.

	Commission staff may contact that individual regarding the confidential information submitted in Part II.				
	Name				
	Title				
	Email				
	Telephone				
II-2a.		ease indicate whether your firm has experienced any of the to the production of silicomanganese since January 1, 2018.			

Check as many as appropriate.		If checked, please describe the nature, timing / duration, and impact on operations of any such reported changes as well as the business reasons for them; leave completely blank if not applicable
	Plant openings	
	Plant closings	
	Prolonged shutdowns	
	Production curtailments	
	Relocations	
	Expansions	
	Acquisitions	
	Consolidations	
	Weather-related or force majeure events	
	Other (e.g., revised labor agreements, technology)	

II-2b.	<u>COVID-19 pandemic.</u> —Has the COVID-19 pandemic or have any government actions taken to contain the spread of the COVID-19 virus resulted in changes in your firm's supply chain arrangements, production, and shipments (including exports to the United States) relating to silicomanganese? In your response, please discuss the duration and timing of any such changes as they relate to your firm's operations.					
	No	s	f yes, describe these changes including the impact over time on the (a) upply chain and (b) production and shipments with respect to ilicomanganese.			
II-2c.	Role of war in Ukraine. —Did the war in Ukraine affect your firm's operations, production of silicomanganese, or exports of silicomanganese to the United States? If yes, please describe what factors affected operations, production, or exports (e.g., power supply, access to seaports shipping routes, etc.).					
	No	Yes	If yes, please describe.			
II-2d.	operations. —Does your firm anticipate any changes in the character of zation relating to the production of silicomanganese in the future?					
	No	Yes	If yes, supply details as to the likely timing, nature, and significance of such anticipated changes and describe the underlying assumptions and business reasons for them.			

II-3a. **Production using same machinery.**—Please report your firm's production of products using the same equipment, machinery, or employees as used to produce silicomanganese, and the combined capacity (both installed and practical capacity) on this shared equipment, machinery, or employees in the periods indicated.

"Installed overall capacity" – The level of production that your establishment(s) could have attained, assuming your firm's optimal product mix, and based solely on existing capital investments, i.e., machinery and equipment that is in place and ready to operate. This capacity measure does <u>not</u> take into account other constraints to production such as existing workforce constraints, availability of raw materials, or downtime for maintenance, repair, and clean-up. This capacity measure is sometimes referred to as "nameplate" or "theoretical" capacity.

"Practical overall capacity" – The level of production that your establishment(s) could reasonably have expected to attain, taking into account your firm's actual product mix over the period. This capacity measure is based on not only existing capital investments, i.e., machinery and equipment that is in place and ready to operate; but also non-capital investment constraints, such as (1) normal operating conditions, including normal downtime for maintenance, repair, and cleanup; (2) your firm's existing in place and readily available labor force; (3) availability of material inputs; and (4) any other constraints that may have limited your firm's ability to produce the reported products. Importantly, this capacity measure is the maximum "practical" production your firm could have achieved without hiring new personnel or expanding the number of shifts operated in the period.

"Practical silicomanganese capacity" – The level of production of silicomanganese that your establishment(s) could reasonably have expected to attain. The same assumptions apply to this capacity measure as for practical overall capacity, but only includes the portion of practical overall capacity allocated to the production of silicomanganese based on the actual product mix experienced over the period.

Takes into account	Installed overall capacity	Practical overall capacity	Practical silicomanganese capacity
Existing capital investments	Yes	Yes	Yes
Product mix	Yes	Yes	Yes
Normal downtime, maintenance, repair and clean-up	No	Yes	Yes
Existing labor force	No	Yes	Yes
Availability of material inputs	No	Yes	Yes
Actual number of shifts and hours operated	No	Yes	Yes
Limited to silicomanganese	No	No	Yes

"Production" —All production in your establishment(s) in China or Ukraine, including production consumed internally within your firm.

II-3a. Production using same machinery. —Continued

	Qua	ntity (in short to	ons)			
Calendar year January-March						
Item	2021	2022	2023	2023	2024	
Capacity measures: Installed overall capacity ¹						
Practical overall capacity ¹²						
Practical silicomanganese capacity ³ ⁴	0	0	0	0	0	
Production of: Silicomanganese ^{3 4}	0	0	0	0	0	
Other out-of-scope products: Ferromanganese						
Ferrosilicon						
Other products ⁵						
Subtotal, all out-of-scope products	0	0	0	0	0	
Total production using same						
machinery or workers	0	0	0	0	0	

¹ Data reported for both "installed overall" and "practical overall" capacity should each individually be greater than data reported for total production (last line). Additionally, data reported for "installed overall" capacity should be greater than "practical overall" capacity in every period.

II-3b. <u>Operating parameters.</u>—The *practical* overall capacity reported in II-3a is based on the following operating parameters:

Hours per week	Weeks per year

II-3c.	<u>Capacity calculations</u> .—Please describe the methodology used to calculate <i>installed</i> and <i>practica</i> overall production capacities reported in II-3a, and explain any changes in reported capacities.	ı

² Please provide details in your response to the question on capacity constraints in question II-3d below that explain the differences reported between "installed" overall capacity and "practical" overall capacity.

³ Data reported for practical silicomanganese capacity should be greater than the data reported for production of silicomanganese in each period, if not revise prior to submission to the Commission. Additionally, if your firm reports the production of no other products on the same machinery and using the same workers as silicomanganese then "practical overall" and "practical silicomanganese" capacity measures should be equal to each other.

⁴ Data entered for this indicator in question II-13 will populate here once reported.

⁵ Please identify these products: _____.

II-3d.	Practical overall production constraints.—Please describe the constraint(s) that set the limit(s) on
	your firm's practical overall capacity over the period reported in question II-3a. If different
	constraints were binding over different periods reported, please specify when each constraint was
	limiting your reported practical overall capacity. If a constraint was not actually binding over the
	period reported, but was still a constraint to achieving the installed capacity level, indicate at what
	level it would have been binding.

	traint ck as many as appropriate)	Obscription (If checked, please describe the details, timing, and duration of the constraint; leave completely blank if not applicable)
	Production bottlenecks	
	Existing labor force	
	Supply of material inputs	
	Fuel or energy	
	Storage capacity	
	Logistics/transportation	
	Other constraints (list the specific constraints in the description field)	
nd th	e additional actions that would be ne	e describe and quantify the amount of time it would take eded (e.g., hiring new workers, expanding shifts, oply, etc.) for your firm to be able to fully utilize the in II-3a.
overal of pro capaci	l capacity, please report, with specific duction) would need to be brought ba	ent that your company is reporting excess installed ity: (1) which machines or equipment (or other elements ack into production for your plant to operate at full such machines or equipment were last used by your

	•	nable to switch production (capacity) between silicomanganese a sing the same equipment and/or labor?	and other
No	Yes	If yes— (i.e., have produced other products or are able to products) Please identify other actual or potential products.	duce oth
		—Please check that the capacity numbers reported in question II	I-3a follo
		—Please check that the capacity numbers reported in question II relevant definitions for capacity.	I-3a follo √ if \
Are all to	nission's r nree capa i <u>pment</u> (i.	relevant definitions for capacity.	•
Are all the and equiparts of the capital in the practice of the capital in the ca	nission's r nree capa ipment (i. nvestmen tical over	Item city measures reported based on currently installed machinery e., the reported capacity level would not require additional	•
Are all the and equivalent capital in Are practice require	nree capa ipment (i. nvestmen tical over d based on hiring add	Item city measures reported based on currently installed machinery e., the reported capacity level would not require additional ts in order to achieve)? call capacity and practical silicomanganese capacity measures on existing labor force (i.e., the reported capacity level would not	•

Note: If your firm is not able to answer "yes" to any of the above criteria as it relates to your firm's reported capacity levels, please revise your capacity numbers to be in conformance with the appropriate definition prior to submission to the Commission.

Does the difference between practical overall capacity and practical

dedicated to the production of out-of-scope products?

silicomanganese capacity equal the portion of practical overall capacity that is

II-6.	<u>Share of sales</u> . —What percentage of your firm's total sales in its most recent fiscal year was represented by sales of silicomanganese? percent.					
II-7.	<u>Firm's estimated share of production in China or Ukraine.</u> —Please estimate the percentage of total production of silicomanganese in the country specified on the certification page accounted for by your firm's production in 2023 percent.					
II-8.	total expo	rts to the	are of exports from China or Ukraine. —Please estimate the percentage of United States of silicomanganese from the country specified on the counted for by your firm's exports in 2023 percent.			
II-9.		-	<u>actions</u> . —Is the silicomanganese exported by your firm subject to ervailing duty/safeguard findings, remedies, or proceedings?			
	No	Yes	If yes— List the product(s), countries affected, and the date of such findings/remedies/proceedings			
II-10a.	Da. Other export markets (increased sales). —Identify export markets (other than the United States) where your firm has increased its sales of silicomanganese since January 1, 2018. Please identify and discuss below.					
II-10b.		nere your f	ets (decreased sales). —Identify export markets (other than the United firm has decreased its sales of silicomanganese since January 1, 2018. Please below.			

II-11.	orders cove your firm's o other marke	ring imports capacity, pro ets, and inve position of t	uty orders. —Describe the significance of the existing antidumping of silicomanganese from China and Ukraine in terms of their effect oduction, home market shipments, exports to the United States and ntories. You may wish to compare your firm's operations before and he orders and consider any new market developments (e.g., geopolism).	on				
II-12.	operations of availability, employmen developmen	Likely impact of revocation. —Would your firm anticipate any changes in the character of its operations or organization considering any new market developments (e.g., geopolitical issues, availability, etc.), including its capacity, production, U.S. shipments, inventories, purchases, employment, revenues, costs, profits, cash flow, capital expenditures, research and development expenditures, or asset values relating to the production of silicomanganese in the future if the antidumping duty orders on silicomanganese from China and/or Ukraine were to be revoked?						
	No	Yes	If yes, supply details as to the likely timing, nature, and significance of such anticipated changes and describe the underlying assumptions and business reasons for them. Include in your response a specific projection of your firm's capacity to produce silicomanganese (in short tons) for 2024 and 2025.					

II-13. <u>Trade data</u>. —Report your firm's capacity, production, shipments, and inventories related to the production of silicomanganese in your establishment(s) in China or Ukraine during the specified periods. Do not include resales of silicomanganese that your firm did not produce in this question; those data to the degree they are exported to the United States should only be reported in question II-15.

<u>Do not submit data by manufacturing facility if they are in the same country.</u> If your firm has multiple manufacturing establishments within one country, you are required to combine data for those establishments within one foreign producer questionnaire response.

<u>Do not submit data on multiple countries combined</u>. The establishments reported here should all be located in the country of the firm's address reported on the certification page. Multinational companies with production in multiple subject countries should submit separate foreign producer questionnaire responses for each subject country.

"Production" —All production in your establishment(s) in China or Ukraine, including production consumed internally within your firm.

"Shipments"—Shipments of products produced in your establishment(s) in China or Ukraine. Quantities reported should be net of returns. Report net values (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods) in U.S. dollars, f.o.b. your point of shipment in China or Ukraine.

"Home market commercial shipments"—Shipments, other than internal consumption and transfers to related firms, within China or Ukraine.

"Home market internal consumption/transfers to related firms"—Shipments made to related firms in China or Ukraine, including product consumed internally by your firm.

"Export shipments"—Shipments to destinations outside China or Ukraine, including shipments to related firms.

"Inventories" — Finished goods inventory, not raw materials or work-in-progress.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the trade data, as Commission staff may contact your firm regarding questions on the trade data. The Commission may also request that your company submit copies of the supporting documents/records (such as production and sales schedules, inventory records, etc.) used to compile these data.

II-13. <u>Trade data</u>. — *Continued*.

		Calendar year	January-March		
Item	2021	2022	2023	2023	2024
Practical silicomanganese					
capacity¹ (Quantity) (A)					
Beginning-of-period					
inventories (B)					
Production (C)					
Home market shipments: Internal consumption/ transfers: Quantity (D)					
Value (E)					
Commercial shipments: Quantity (F)					
Value (G)					
Export shipments: to the United States: Quantity (H)					
Value (I)					
to Canada and Mexico: <i>Quantity</i> (J)					
Value (K)					
to Europe: Quantity (L)					
Value (M)					
to Asia: ³ <i>Quantity</i> (N)					
Value (O)					
to all other markets: ⁴ <i>Quantity</i> (P)					
Value (Q)					
Total exports: (Quantity) (R)	0	0	0	0	C
Total shipments: (<i>Quantity</i>) (S)	0	0	0	0	(
End-of-period inventories: (T)					
 Report your firm's practical sil question II-3a. Identify your firm's principal E Identify your firm's principal A Identify your firm's principal O 	<i>uropean</i> export r I <i>sian</i> export mark	markets: ets:	with the definition	s and instructions ir	ncluded in

II-13. <u>Trade data</u>. —*Continued*.

⁴ Identify your firm's principal *other* export markets: ___

RECONCILIATION OF SHIPMENTS, PRODUCTION, AND INVENTORY. —Generally, the data reported for the end-of-period inventories (i.e., line T) should be equal to the beginning-of-period inventories (i.e., line B), plus production (i.e., line C), less total shipments (i.e., lines D, F, H, J, L, N, and P). Please ensure that any differences are not due to data entry errors in completing this form, but rather actually reflect your firm's records; and also provide any likely explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

	Calendar year			January-March		
Item	2021	2022	2023	2023	2024	
B+C-D-F-H-J-L-N-P-T= should equal zero ("0") or provide an explanation. ¹	0	0	0	0	0	
¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless accurate:						

II-14. Exports not produced by your firm. —Report your firm's exports of silicomanganese that were produced in China or Ukraine but not by your firm during the specified periods. Note these data should <u>not</u> be included in question II-13.

		Calendar year	January-March		
Item	2021	2022	2023	2023	2024
Exports of silicomanganese not produced by your firm ¹ :					
to the United States: Quantity (U)					
Value (V)					
to Canada/Mexico: Quantity (W)					
Value (X)					
to Europe:² Quantity (Y)					
Value (Z)					
to Asia: ³ <i>Quantity (AA)</i>					
Value (AB)					
to all other markets: ⁴ <i>Quantity (AC)</i>					
Value (AD)					

II-15. <u>Total shipments of silicomanganese by grade</u>. —Report your firm's total shipments of silicomanganese by grade (ASTM A, ASTM B, ASTM C, high phosphorus, and other) during the specified periods.

Quantity (in short tons) and Value (in \$1,000s)							
		Calendar year	January-March				
Item	2021	2022	2023	2023	2024		
ASTM A:							
Quantity (AE)							
Value (AF)							
ASTM B: Quantity (AG)							
Value (AH)							
ASTM C:							
Quantity (AI)							
Value (AJ)							
High phosphorus not meeting ASTM standard (more than							
0.2% phosphorus content): Quantity (AK)							
Value (AL)							
Other:1							
Quantity (AM)							
Value (AN)							
¹ Identify other products:							

<u>RECONCILIATION OF TOTAL SHIPMENTS BY GRADE</u>. —Please ensure that the quantities and values reported for total shipments of silicomanganese by grade (i.e., lines AE through AN) in each time period equal the quantity and value reported for total shipments (i.e., lines D through Q in II-13 and lines U through AD in II-14) in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

		Calendar year		January-March	
Reconciliation item	2021	2022	2023	2023	2024
D+F+H+J+L+N+P-U-W-Y -AA-AC-AE-AG-AI-AK-AM = zero ("0"), if not revise.	0	0	0	0	0
E+G+I+K+M+O+Q-V-X-Z -AB-AD-AF-AH-AJ-AL-AN = zero ("0"), if not revise.	0	0	0	0	0

II-16.	Other explanations. —If your firm would like to further explain a response to a question in Part II for which a narrative box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section.

PART III. — MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Craig Thomsen (202-205-3226, craig.thomsen@usitc.gov).

III-1. <u>Contact information</u>. —Please identify the responsible individual and how Commission staff may contact the individual regarding the confidential information submitted in Part III.

Name	
Title	
Email	
Telephone	

III-2. <u>Contract versus spot</u>. —Approximately what share of your firm's sales (i.e., including home market sales, exports to the United States, and exports to other markets) of silicomanganese in 2023 were on the basis of (1) short-term contracts, (2) annual contracts, (3) long-term contracts, and (4) spot sales?

	Short-term contracts (multiple deliveries for less than 12 months)	Annual contracts (multiple deliveries for 12 months)	Long-term contracts (multiple deliveries for more than 12 months)	Spot sales (for a single delivery)	Tota (shou sum t 100.0	ld to
Share of your 2023 sales	%	%	%	%	0.0	%

III-3. Changes in factors affecting supply. Have changes in any factors affecting supply (e.g., changes in availability or prices of energy or labor; transportation conditions; capacity and/or methods of production; technology; export markets; or alternative production opportunities) affected the availability of silicomanganese produced in the country specified on the certification page for export to the U.S. market, other export markets, or the home market, since January 1, 2018?

No	Yes	If yes, please describe.

III-4. <u>Future export supply</u>. —Do you anticipate any changes in terms of the availability of silicomanganese produced in the country specified on the certification page for export to the U.S. market in the future?

Increase	No change	If you anticipate changes in supply, please identify the changes, including the timing and impact of such changes on shipment volumes and prices of exports to the United States.

	the U.S. r contracts barriers s firm from	market ar , other sa uch as ta	Describe how easily your firm can shift its sales of silicomanganese between ad alternative third country markets. In your discussion, please describe any ales arrangements, or other constraints (including any third-country trade riffs, quotas, or other non-tariff barriers) that would prevent or impede your exports of silicomanganese between the U.S. and alternative country markets period.
	home ma	_	Is the product range, product mix, or marketing of silicomanganese in your erent from that for your exports of silicomanganese to the United States or to kets?
	No	Yes	If yes, please explain.
	or marke	ting of sil t to third	—Have there been any significant changes in the product range, product mix, icomanganese in your firm's home market, for export to the United States, or country markets since January 1, 2018, or do you anticipate any future
	No	Yes	If yes, please describe the changes, including the market(s) affected and when these changes occurred or are expected to occur.
			ve there been any changes in the number or types of products that can be comanganese since January 1, 2018, or do you anticipate any future changes?
	substitut	ed for sili	If yes, explain the changes, noting when these changes occurred or are
I-9.	No Interchar	Yes ngeability	If yes, explain the changes, noting when these changes occurred or are
-9.	No Interchar	Yes ngeability	If yes, explain the changes, noting when these changes occurred or are expected to occur. If yes, explain the changes, noting when these changes occurred or are expected to occur. In the silicomanganese produced by your firm and sold in its home market the expected in the same applications) with your firm's silicomanganese.

III-10.	End use	<u>es</u> . —								
	(a)	home	Do the end uses of the silicomanganese that your firm manufactures and sells to your home market differ from those of the silicomanganese your firm exports to the U.S. market or to third-country markets?							
		No	Yes	If yes, please explain the differences.						
	(b) Have there been any changes in the end uses of silicomanganese since Januor do you anticipate any future changes?									
		No	Yes	If yes, explain the changes, noting when these changes occurred or are expected to occur.						

III-11. <u>Demand trends.</u> — Has demand in the following markets for silicomanganese steadily increased, fluctuated but ended higher, not changed, fluctuated but ended lower, or steadily decreased in the following time periods, and how do you anticipate demand will change in the future? Explain any trends and describe the principal factors that have affected, and that you anticipate will affect, these changes in demand.

Market	Steadily increase	Fluctuate higher	No change	Fluctuate lower	Steadily decrease	Explanation and factors					
	Demand between January 1, 2018 & December 31, 2020										
Home market											
United States											
Other markets											
		D	emand si	nce January	, 1, 2021						
Home market											
United States											
Other markets											
			Anticipat	ed future d	emand						
Home market											
United States											
Other markets											

III-12.	<u>War in Ukraine</u> .—Has your home market or the global market for silicomanganese experienced any changes or issues related to the war in Ukraine since February 2022 (e.g., supply,									
	transport	ation, tariff	treatme	nt, etc	c.)? Ar	e there any changes or issues related to the war in foreseeable future?				
		Period		No	Yes	If yes, please describe.				
	Since Fel	bruary 2022								
	Anticipat	ted changes	/issues							
III-13.	<u>Price comparisons.</u> —Please compare market prices of silicomanganese in your firm's home market, the United States, and third-country markets. Provide information as to time periods and regions for any price comparisons and note the sources for your market knowledge.									
III-14.	14. <u>Description of home market</u> . —Describe briefly your firm's home market for silicomanganese, including the number of suppliers serving the market and the degree of competition between them.									
III-15.	-	ompetition. 's home ma		your f	irm fa	ce competition from imports of silicomanganese in				
	No	Yes If	yes, plea	se ide	entify	the country sources of these imports.				
III-16.	6. Role of section 301 tariffs. — Did the U.S. tariffs on Chinese-origin products under section 301, or changes in these tariffs, have an impact on your firm's exports of silicomanganese to the United States?									
	No	Y	es If	yes, p	olease	describe.				
		l	<u> </u>							

III-17.	Other explanations. —If your firm would like to further explain a response to a question in Part III for which a narrative box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section.


Correcting valid number error messages. —If you are completing this questionnaire in a country that uses periods (".") to delineate multiples of 1000 (e.g., one million would appear as \$1.000.000 instead of as \$1,000,000), you may be unable to enter in numbers greater than 999 in numeric form fields. This issues stem from your computer number formatting setting (e.g., not the MS Word document itself, but the computer from which you are opening up the document). In the United States commas (,) delineate multiples of 1000 and periods (.) delineate fractions less than one. Many EU countries use the reverse where multiples of 1000 are delineated with periods (.) and fractions less than one are delineated with commas (,). This questionnaire is prepared in the United States with the U.S. number formatting. When this formatting interacts with a computer set to EU number formatting, we believe this may cause this issue.


The solution to this data entry issue is to temporarily change your operating system's number formatting to be consistent with the U.S. number formatting system while you complete the questionnaire.

To temporarily change your computer's number settings to U.S. settings, please do the following (for Microsoft Windows Operating system):

- START
- Control Panel
- Region and Language (under Clock, Language, and Region category)
- Format tab
- Change the Format from your existing one (e.g., "Italian (Italy)") to "English (United States)" (see screen shots below)

When you do this the number "twelve million dollars and thirty-five cents" would change from \$12.000.000,35 (Italy format) to \$12,000,000.35 (U.S. format), and then there will be no conflict with the USITC foreign producer questionnaire form. When you finish reporting the data then you can close the questionnaire and switch back to your country settings.





HOW TO FILE YOUR QUESTIONNAIRE RESPONSE

This questionnaire is available as a "fillable" form in MS Word format on the Commission's website at: https://usitc.gov/reports/active_import_injury_questionnaires.

Please do not attempt to modify the format or permissions of the questionnaire document. Please submit the completed questionnaire using one of the methods noted below. If your firm is unable to complete the MS Word questionnaire or cannot use one of the electronic methods of submission, please contact the Commission for further instructions.

• <u>Upload via Commission's secure submission portal</u>. — The questionnaire must be uploaded in two formats: (1) a Microsoft Word 97-2003 document; and (2) a PDF copy of the complete questionnaire with a signature on the first page and, if your firm is a party to the proceeding (see below), a certificate of service attached to the end of the document.

Web address: https://usitc.gov/qportal Pin: SIMN Phase: Fifth Review

• E-mail. — E-mail the MS Word questionnaire to <u>Tyler.Berard@usitc.gov</u>; include a PDF copy of the complete questionnaire with a signature on the first page. Submitters are strongly encouraged to encrypt nonpublic documents that are electronically transmitted to the Commission to protect your sensitive information from unauthorized disclosure. The USITC secure submission portal and the Electronic Document Information System (EDIS) use Federal Information Processing Standards (FIPS) 140-2 cryptographic algorithms to encrypt data in transit. Submitting your nonpublic documents by a means that does not use these encryption algorithms (such as by email) may subject your firm's nonpublic information to unauthorized disclosure during transmission. If you choose a non-encrypted method of electronic transmission, the Commission warns you that the risk of such possible unauthorized disclosure is assumed by you and not by the Commission.

If your firm did not produce or export this product, please fill out page 1, print, sign, and submit a scanned PDF copy via the Commission's secure submission portal or email.

<u>Parties to this proceeding</u>. — If your firm is a party to this proceeding, it is required to serve a copy of the completed questionnaire on parties to the proceeding that are subject to administrative protective order (see 19 CFR § 207.7). A list of such parties may be obtained from the Commission's Secretary (202-205-1802). A certificate of service must accompany the completed questionnaire you submit (see 19 CFR § 207.7). Service of the questionnaire must be made in paper form.